Skip to main navigation

Skip to content

About Us
Investors
Pipeline
Contact Us
We're Hiring

About Us
Investors
Pipeline
Contact Us
We're Hiring

About Us
Investors
Pipeline
Contact Us
We're Hiring

About Us
Investors
Pipeline
Contact Us
We're Hiring

Press Releases

Press Releases
Events & Presentations

2022
2021
2020
2019

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Jun 23, 2022

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

Jun 08, 2022

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

Jun 02, 2022

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 13, 2022

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

May 04, 2022

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

May 03, 2022

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

Apr 25, 2022

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Apr 25, 2022

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

Apr 06, 2022

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

Mar 30, 2022

Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

Mar 22, 2022

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022

Mar 10, 2022

Cognition Therapeutics Announces Participation in March Investment Conferences

Mar 08, 2022

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

Feb 08, 2022

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

Jan 10, 2022

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

Jan 04, 2022

Terms of Use
Privacy Policy
FCOI Policy

Copyright© 2022 Cognition Therapeutics, Inc. All rights reserved